Helicobacter pylori et néoplasies gastriques

J. -D. de Korwin1
1Service de médecine interne H et Groupe d’étude français des hélicobacters, CHU, hôpital Central, Nancy Cedex, France

Tóm tắt

Helicobacter pylori (H. pylori) est un agent carcinogène majeur des lymphomes gastriques du MALT (mucosa associated lymphoid tissue) et des adénocarcinomes gastriques, qui peuvent co-exister chez un même patient. Les lymphomes du MALT peuvent guérir après éradication de l’infection gastrique. Le rôle de H. pylori dans la cancérogenèse gastrique est attesté par les études épidémiologiques, les modèles animaux et son implication dans le processus d’atrophie gastrique, l’hypochlorhydrie et la mutagenèse. Interviennent des facteurs bactériens (îlot de pathogénicité cag...), environnementaux (alimentation...) et de l’hôte (polymorphisme génétique des cytokines inflammatoires). L’éradication préventive de H. pylori est indiquée en cas d’antécédents familiaux de cancer gastrique au premier degré et après résection gastrique partielle pour cancer. D’autres groupes à risque des néoplasies gastriques sont étudiés.

Tài liệu tham khảo

Conclusions et recommandations révisées du groupe de travail. (1999) Conférence de consensus Helicobacter pylori-Révision 1999. Gastroenterol Clin Biol 23: C95–C104 Malfertheiner P, Mégraud F, O’Morain C, et al. (2002) Current concepts in the management of Helicobacter pylori infection. The Masstricht 2000 Consensus Report. Aliment Pharmacol Ther 16: 167–80 De Korwin JD, Lozniewski A (2000) Helicobacter pylori: notions fondamentales et perspectives. Encycl Med Chir Gastroentérologie 9-000-B-60, p 8 Kuipers EJ, Michetti P (2005) Bacteria and mucosal inflammation of the gut:lessons from Helicobacter pylori. Helicobacter 10(Suppl 1):66–70 Israel DA, Peek RM Jr (2006) The role of persistence in Helicobacter pylori pathogenesis. Curr Opin Gastroenterol 22(1): 3–7 De Korwin JD, Frédéric M (2003) Les gastrites chroniques. EMC Gastroentérologie, 9-017-A-10 Peek RM Jr, Crabtree JE (2006) Helicobacter infection and gastric neoplasia. J Pathol 208: 233–248 De Korwin JD (2004) Infection et lymphomes du MALT. Quoi de neuf? Rev Med Interne 25: 545–547 Boot H, de Jong D (2002) Gastric lymphoma: the revolution of the past decade. Scand J Gastroenterol 236: 27–36 Liu H, Ye H, Ruskone-Fourmestraux A, et al. (2002) T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to Helicobacter pylori eradication. Gastroenterology 122: 1286–1294 Wundisch T, Thiede C, Morgner A, et al. (2005) Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 23: 8018–8024 Chen LT, Lin JT, Tai JJ, et al. (2005) Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 97: 1345–1353 Levy M, Copie-Bergman C, Traulle C, et al. (2002) Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol 97: 292–297 Suerbaum S, Michetti P (2002) Helicobacter pylori infection. N Engl J Med 347: 1175–1186 Serafini M, Belloco R, Wolk A, et al. (2002) Total antioxydant potential of fruit and vegetables and risk of gastric cancer. Gastroenterology 123: 985–991 Helicobacter and cancer collaborative group. (2001) Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49: 347–353 Ekstrom AM, Held M, Hansson LE, et al. (2001) Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 121: 784–791 Inoue M, Tajima K, Matsuura A, et al. (2000) Severity of chronic atrophic gastritis and subsequent gastric cancer occurrence: a 10-year prospective cohort study in Japan. Cancer Letters 161: 105–112 El-Omar EM, Oien K, Murray LS, et al. (2000) Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of Helicobacter pylori. Gastroenterology 118: 22–30 Kuipers EJ (1999) Review article: exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther 13(suppl 1):3–11 Ando T, Goto Y, Maeda O, et al. (2006) Causal role of Helicobacter pylori infection in gastric cancer. World J Gastroenterol 12: 181–186 Shimizu N, Ikehara Y, Inada K, et al. (2000) Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 60: 1512–1514 Uemura N, Okamoto S, Yamamoto S, et al. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789 Nogueira C, Figueiredo C, Carneiro F, et al. (2001) Helicobacter pylori genotypes may determine gastric histopathology. Am J Pathol 158: 647–54 Sepulveda AR, Graham DY (2002) Role of Helicobacter pylori in gastric carcinogenesis. Gastroenterol Clin N Am 31: 517–535 Figueiredo C, Machado JC, Pharoah P, et al. (2002) Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 94: 1662–1663 Guarner J, Herrera-Goepfert R, Mohar A, et al. (2003) Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. Hum Pathol 34: 28–31 Vaananen H, Vauhkonen M, Helske T, et al. (2003) Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 15: 885–891 Wong BC, Lam SK, Wong WM, et al. (2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291: 187–194 Uemura N, Okamoto S (2000) Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol Clin North Am 29: 819–827 Malfertheiner P, Sipponen P, Naumann M, et al. (2005) Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 100: 2100–2115